BOSTON, April  28, 2026  (GLOBE NEWSWIRE) -- Block &amp; Leviton is investigating Erasca, Inc. (NASDAQ:ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment

ERAS

Erasca, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors to Contact the Firm to Possibly Recover Losses

Erasca Faces Legal Challenges After Patent Infringement Allegations

Erasca Inc. (NASDAQ:ERAS) said it intends to vigorously contest allegations made by Revolution Medic...

Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BOSTON, April  28, 2026  (GLOBE NEWSWIRE) -- Block &amp;amp; Leviton is investigating Erasca, Inc. (NASDAQ:ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Erasca, Inc. (NASDAQ: ERAS) is facing a severe decline after receiving allegations from Revolution Medicines regarding patent infringement related to its drug ERAS-0015. This news comes alongside the company’s announcement of preliminary Phase 1 results, raising concerns about the legal and commercial viability of its product.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Erasca shares fell over 45% after patent infringement allegations.</li><li>Revolution Medicines claimed ERAS-0015 violates its patent rights.</li><li>Block &amp; Leviton investigating potential securities law violations by Erasca.</li><li>Erasca&#039;s preliminary Phase 1 data release coincided with the allegations.</li><li>Investors who lost money may pursue legal recovery through Block &amp; Leviton.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Revolution Medicines (RVMD)</strong>: Allegations from Revolution may impact Erasca&#039;s drug ERAS-0015.</li><li><strong>Block &amp; Leviton (N/A)</strong>: Law firm investigating potential securities violations by Erasca.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>The article falls under legal developments as it highlights potential securities law violations affecting Erasca. This legal challenge could hinder investor confidence and affect the stock&#039;s performance in the near term.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Erasca&#039;s share price could face further pressure from ongoing legal investigations.</li><li>Potential patent disputes with Revolution Medicines may delay product timelines.</li><li>Investor sentiment may worsen if further legal issues are disclosed.</li><li>Loss recovery efforts could distract from Erasca&#039;s operational focus.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Erasca shares fell over 45% on April 28, 2026.</li><li>Revolution Medicines alleges patent infringement and trade secret misappropriation.</li><li>Erasca announced preliminary Phase 1 dose-escalation data the same day.</li><li>Block &amp; Leviton is investigating securities law violations related to ERAS.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Expect continued volatility in ERAS shares, potentially downward, in the short term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>BOSTON, April  28, 2026  (GLOBE NEWSWIRE) -- Block &amp; Leviton is investigating Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment should <a href="https://www.globenewswire.com/Tracker?data=I_-6sSwao4g1AzEzeVk3SYf55ozazzlRuB0xZAz8U8uYHcl-rQwkdBj7G4Lh5-DzbkkkDEwepM1hKKjazu0oTX3nuUI8OKu5rxcSeJlMK3o=" rel="nofollow" target="_blank">contact the firm</a> to learn more about how they might recover those losses. For more details, visit <a href="https://www.globenewswire.com/Tracker?data=hj27ZtGS0EBHcXPpkLEjFNrLQ9TU8pKYkFe0398INMZam4ZA0sSkxb_H6xxKBAYjV2I5-Zz0IktreJebxxqisIM3GmOiPa61ZB5FPt48eiN0nj-K3e6fFjxF6j_o6noWa5weoxdtFcHymGS7-FwF6A==" rel="nofollow" target="_blank">https://blockleviton.com/cases/eras</a>.</p>  <p><strong>What is this all about?</strong></p>  <p>Shares of Erasca fell over 45% in premarket trading on April 28, 2026, after the company disclosed that it received a letter from Revolution Medicines alleging that Erasca's ERAS-0015 infringes a Revolution patent and is connected to alleged trade secret misappropriation. The disclosure came the same day Erasca announced preliminary Phase 1 dose-escalation data for ERAS-0015.</p>  <p><strong>Who is eligible?</strong></p>  <p>Anyone who purchased Erasca, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should <a href="https://www.globenewswire.com/Tracker?data=I_-6sSwao4g1AzEzeVk3SfdM8sYiW-iSkcs11BuPk3PtX05ki8x00v3gX0BOob9anF2t6Hr1Pt80Hsoo4qb2PTK2W95uNG5PYf5hV4i6K8pxpaOi_gs0e4j-sLvqRbZs" rel="nofollow" target="_blank">contact Block &amp; Leviton</a> to learn more.</p>  <p><strong>What is Block &amp; Leviton doing?</strong></p>  <p>Block &amp; Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.</p>  <p><strong>What should you do next?</strong></p>  <p>If you&#39;ve lost money on your investment, you should contact Block &amp; Leviton to learn more via our <a href="https://www.globenewswire.com/Tracker?data=REJOuzbjCote_CcQf64s3UpUwygyUtnY_8BsvsjbQjK6scrZOkme6647ymoDeuAvTBd1vL_En53gQzzFELUGgc7JZRubHBBjQltNM7B3peQ=" rel="nofollow" target="_blank">case website</a>, by email at <a href="https://www.globenewswire.com/Tracker?data=vNL6bKnerhYQdcI-STRTby6SvCRmZm70q-C46CJyYpGNWOJyJ8mMgEi0cIaUiksHuy3md6BuSKmSezjxK1_HsNEVGcL90Cv9q9SGw9qRWf67nCBGKfqVYiQYmQ4yvRAt" rel="nofollow" target="_blank">shareholders@blockleviton.com</a>, or by phone at (888) 256-2510.</p>  <p><strong>Whistleblower?</strong></p>  <p>If you have non-public information about Erasca, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block &amp; Leviton at <a href="https://www.globenewswire.com/Tracker?data=vNL6bKnerhYQdcI-STRTby6SvCRmZm70q-C46CJyYpHVR4Hzk5FxkWOM99MrsjpcfjGFRhtcgAfu9F4OR0iBKFeSzt9hjMTNRxss2sSGz0idEfnquNLjNDpwhKBH056Q" rel="nofollow" target="_blank">shareholders@blockleviton.com</a> or by phone at (888) 256-2510.</p>  <p><strong>Why should you contact Block &amp; Leviton?</strong></p>  <p>Block &amp; Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation&#39;s top institutional investors hire us to represent their interests. You can learn more about us at our website <a href="https://www.globenewswire.com/Tracker?data=C0UabEJMy07nWNoMYEZTfPDJ7HZYN8tjMGNkgI7D0xXV2ljZBHC7Gezc3Z7wHL8nRqDiWjrnR_3wf5EwntWeJulFWEvZA1qUO_pF__8ZOeA=" rel="nofollow" target="_blank">www.blockleviton.com</a>, call (888) 256-2510 or email <a href="https://www.globenewswire.com/Tracker?data=vNL6bKnerhYQdcI-STRTby6SvCRmZm70q-C46CJyYpGdglQdW9U0xCWEpWy711Af0Bi46utwtS-Tjiz_7rdulC9cDC_bcHR4b3U1Fl-3y5Xop5CWS5VRWZRujZadiJy0" rel="nofollow" target="_blank">shareholders@blockleviton.com</a> with any questions.</p>  <p>This notice may constitute attorney advertising.</p>  <p><em>CONTACT:</em><br></br><em>BLOCK &amp; LEVITON LLP</em><br></br><em>260 Franklin St., Suite 1860</em><br></br><em>Boston, MA 02110</em><br></br><em>Phone: (888) 256-2510</em><br></br><em>Email: <a href="https://www.globenewswire.com/Tracker?data=vNL6bKnerhYQdcI-STRTby6SvCRmZm70q-C46CJyYpHrnXgk5xS9malaD8T9IKxQHOjDp3Off_UgLHTO0iDDJ7bqB6vcNjW1n8AbfnNLw_emSFgSVjqpwOy_FR08-O1p" rel="nofollow" target="_blank">shareholders@blockleviton.com</a></em></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwODU2NiM3NTcwNDM2IzIwMTgxMTk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODgxZGQyY2ItMTA5Zi00ZmU4LWFlOGEtM2ZiNmIzY2ViNjYzLTEwMjk2OTAtMjAyNi0wNC0yOC1lbg==/tiny/Block-Leviton-LLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/582f8ff5-dda1-458c-b0b6-cc833c566289"><img src="https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg" border="0" width="150" height="45" alt="Primary Logo"></img></a></p>

Erasca, Inc. (NASDAQ: ERAS) is facing a severe decline after receiving allegations from Revolution Medicines regarding patent infringement related to its drug ERAS-0015. This news comes alongside the company’s announcement of preliminary Phase 1 results, raising concerns about the legal and commercial viability of its product.

Erasca, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors to Contact the Firm to Possibly Recover Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News